The systemic and SmD183-119-autoantigen-specific cytokine memory of Th cells in SLE patients

Rheumatology

Volumn 46, Issue 2, 2007, Pages 238-245

  Langer, S ^a   Langnickel, D ^a   Enghard, P ^a   Undeutsch, R ^a   Burmester, G R ^a   Hiepe, F ^a,b   Radbruch, A ^b   Riemekasten, Gabriela ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Natl Research Cent for   (Germany)

Author keywords

Autoantigens; Cytokine memory; IL 10+ T cells; SLE; T cell cytokines

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 2; IONOMYCIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN ANTIBODY; PROTEIN SMD1[83-119]; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; CD3 ANTIGEN; PEPTIDE FRAGMENT; SM NUCLEAR ANTIGENS; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ARTICLE; CELL CULTURE; CELL STIMULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DONOR; EX VIVO STUDY; HELPER CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; INTRACELLULAR SPACE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUPERNATANT; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOSYNTHESIS; HOSPITALIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD3; AUTOANTIGENS; CELLS, CULTURED; CYTOKINES; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846689677     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel180     Document Type: Article

References (39)

1. Theocharis S, Sfikakis PP, Lipnick RN, Klipple GL, Steinberg AD, Tsokos GC. Characterization of in vivo mutated clones from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1995;74:135-42.
2. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
3. Murray LJ, Lee R, Martens C. In vivo cytokine gene expression in T-cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Eur J Immunol 1990;20:163-70.
4. Voll RE, Roth EA, Girkontaite I et al. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 1997; 40:2162-71.
5. Muehlinghaus G, Cigliano L, Huehn S et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B-cells into plasma cells. Blood 2005;105:3965-71.
6. Clinchy B, Moller G. Interleukin-4 induces in vitro migration in naive B-cells through direct mechanisms. Scand J Immunol 1994;40:429-36.
7. Goodman DJ, Gaff C, Gerondakis S. The IL-4 induced increase in the frequency of resting murine splenic B-cells expressing germline Ig heavy chain gamma 1 transcripts correlates with subsequent switching to IgG1. Int Immunol 1993;5:199-208.
8. Banchereau J, Briere F, Liu YJ, Rousset F. Molecular control of B lymphocyte growth and differentiation. Stem Cells 1994;12:278-88.
9. Smith CI, Norberg R, Isenberg D et al. Anti-DNA antibody synthesis after bone marrow transplantation: Implications for IgG subclass restrictivity and pathogenicity of autoantibodies. Bone Marrow Tranplant 1988;3:583-8.
10. Yin Z, Bahtiyar G, Zhang et al. IL-10 regulates murine lupus. J Immunol 2002;169:2148-55.
11. Beebe AM, Cua DJ, de Waal Malefyt R. The role of interleukin-10 in autoimmune disease: Systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 2002; 13:403-12.
12. Riemekasten G, Langnickel D, Enghard P et al. Immune tolerance to the SmD183-119 peptide postpones development of murine lupus and induces regulatory Trl cells. J Immunol 2004;173:5835-42.
13. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 2004; 50:3161-9.
14. Cassese G, Arce S, Hauser AE et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003;171:1684-90.
15. Hauser AE, Muehlinghaus G, Manz RA et al. Long-lived plasma cells in immunity and inflammation. Ann NY Acad Sci 2003;987:266-9.
16. Assenmacher M, Lohning M, Scheffold A et al. Commitment of individual Th1-like lymphocytes to expression of IFN-gamma versus IL-4 and IL-10: selective induction of IL-10 by sequential stimulation of naive Th cells with IL-12 and IL-4. J Immunol 1998;161:2825-32.
17. Richter A, Lohning M, Radbruch. Instruction for cytokine expression in T helper lymphocytes in relation to proliferation and cell cycle progression. J Exp Med 1999;190:1439-50.
18. Schneider S, Bruns A, Moewes B et al. Simultaneous cytometric analysis of (auto)antigen-reactive T and B-cell proliferation. Immunobiology 2002;206:484-95.
19. Helsloot J, Sturgess A. T-cell reactivity to Sjogren's syndrome related antigen La(SSB). J Rheumatol 1997;24:2340-7.
20. Nagy G, Pallinger E, Antal-Szalmas P et al. Measurement of intracellular interferon-gamma and interleukin-4 in whole blood T lymphocytes from patients with systemic lupus erythematosus. Immunol Lett 2001;74:207-10.
21. Filaci G, Grasso I, Contini P et al. DsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: Correlation with clinical disease activity. Clin Exp Rheumatol 1996;14:543-50.
22. McCutcheon M, Wehner N, Wensky A et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immuol Meth 1997;210:149-66.
23. Tan EM, Cohen AS, Fries et al. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
24. Bombardier C, Gladman D, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
25. Atherton E. Solid phase peptide synthesis: A practical approach. Oxford: IRL press, 1989.
26. Riemekasten G, Marell J, Trebeljahr G et al. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest 1998;102:754-63.
27. Hiepe F, Kiessig S, Jahn HD et al. A sensitive and class specific solid phase enzyme immunoassay for anti-DNA autoantibodies in supernatants of lymphocytes cultures and human hybridomas. Biomed Biochem Acta 1986;45:K29-35.
28. Riemekasten G, Kawald A, Weiss C et al. Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide. Arthritis Rheum 2001;44:2435-45.
29. Riemekasten G, Langnickel D, Ebling FM et al. Identification and characterization of SmD183-119-reactive T-cells that give T-cell help for pathogenic anti-dsDNA antibodies. Arthritis Rheum 2003; 48:475-85.
30. 83-119 C-terminal peptide in patients with systemic lupus erythematosus. Ann Rheum Dis 2002;61:779-85.
31. Cabrespines A, Laderach D, Lebosse C, Bach JF, Koutouzov S. Isolation and characterization of apoptotic nucleosomes, free and complexed with lupus autoantibody generated during hybridoma B-cell apoptosis. J Auto Immun 1998;11:19-27.
32. Deguchi Y, Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol 1991;85:392-5.
33. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989;52:421-34.
34. Chang DM, Su WL, Chu SL. The expression and significance of intracellular T helper cytokines in systemic lupus erythematosus. Immunol Invest 2002;31:1-12.
35. D'Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P. Systemic lupus erythematosus candidate genes in the Italian population: Evidence for a significant association with interleukin-10. Arthritis Rheum 2000;43:120-8.
36. Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
37. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the IL-10 receptor. Annu Rev Immunol 2001; 19:683-765.
38. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44.
39. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 anti-bodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.